Acticor Sky VR-T, Rivacor Sky VR-T, Rivacor Rise VR-T, Rivacor Aura VR-T, Acticor Sky VR-T DX, Rivacor Sky VR-T DX, Riva
Biotronik, Inc. · Decision date Sep 25, 2026
What did the FDA decide?
The FDA record shows a 30-Day Notice for PMA supplement P980023/S151 from Biotronik, Inc., decided OK30 on 2026-09-25. The reported purpose is to update manufacturing processes for high voltage capacitors used in ICDs and CRT-Ds. The listed products include Acticor Sky VR-T, Rivacor Sky VR-T, Rivacor Rise VR-T, Rivacor Aura VR-T and the associated DX variants, under product code LWS.
The S151 suffix ties the notice to original PMA P980023, but a supplement is not a new approval of the whole system, and a manufacturing notice is not an original PMA. The database fields do not identify which capacitor supplier, facility, or process step changed, or what evidence supported the decision; the reported purpose is not independent proof of safety or clinical effectiveness.
FDA approval order statement
to update manufacturing processes for high voltage capacitors in ICDs and CRT-Ds
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- Sep 25, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P980023/S151
- Regulatory pathway
- PMA supplement
- Applicant
- Biotronik, Inc.
- Product code
- LWS
- Decision code
- OK30
- Decision date
- Sep 25, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Implantable cardioverter defibrillator (non-CRT).
- Applicant
- Biotronik, Inc.
- Product code
- LWS
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P980023. Subsequent supplements may change the device or its indications.
FDA decision timeline
P980023 · Original PMA
PHYLAX IMPLANTABLE CARDIOVERTER DEFIBRILLATOR SYSTEM
P980023/S151 received
Application receipt date recorded by FDA.
P980023/S150 · Related supplement
Pamira S 60; Pamira S 65; Pamira S 75; Pamira SD 60/16; Pamira SD 65/16; Pamira SD 65/18; Pamira SD 75/18; Pamira S DX 6
P980023/S146 · Related supplement
Acticor Sky VR-T, Rivacor Sky VR-T, Rivacor Rise VR-T, Rivacor Aura VR-T, Acticor Sky VR-T DX, Rivacor Sky VR-T DX, Riva
P980023/S140 · Related supplement
Ilivia Neo 7 VR-T DX 429530; Intica Neo 7 VR-T DX 429559; Intica Neo 5 VR-T DX 429569
P980023/S151 · FDA decision
30-Day Notice
P980023/S149 · Related supplement
Acticor Sky VR-T 481989; Rivacor Sky VR-T 481984; Rivacor Rise VR-T 482020; Rivacor Aura VR-T 482015; Acticor Sky VR-T D
P980023/S152 · Related supplement
Ilivia Neo 7 VR-T DX DF-1 ProMRI, Ilivia Neo 7 VR-T DF-1 ProMRI, Intica Neo 7 VR-T DX DF-1 ProMRI, Intica Neo 7 VR-T DF-
P980023/S153 · Related supplement
Ilivia Neo 7 VRT DX, Intica Neo 7 VRT DX, Intica Neo 5 VRT DX, Acticor Sky VR-T, Rivacor Sky VR-T, Rivacor Rise VR-T, Ri
Timeline entries are records held by MedtechLedger for P980023. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P980023
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Biotronik, Inc. | PMA approval | Oct 27, 1998 | FDA | |
| Biotronik, Inc. | PMA supplement | Sep 10, 2026 | FDA | |
| Biotronik, Inc. | PMA supplement | Sep 17, 2026 | FDA | |
| Biotronik, Inc. | PMA supplement | Sep 25, 2026 | FDA | |
| Biotronik, Inc. | PMA supplement | Oct 9, 2026 | FDA | |
| Biotronik, Inc. | PMA supplement | Oct 13, 2026 | FDA | |
| Biotronik, Inc. | PMA supplement | Oct 22, 2026 | FDA |
Explore the linked device profile
Other records with product code LWS
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| ABBOTT MEDICAL | PMA supplement | Nov 5, 2026 | FDA | |
| Medtronic Cardiac Rhythm Disease Management | PMA supplement | Nov 4, 2026 | FDA | |
Cobalt MRI ICD, Cobalt XT MRI ICD, Crome MRI ICDP980016/S967 | Medtronic Cardiac Rhythm Disease Management | PMA supplement | Oct 29, 2026 | FDA |
| Medtronic Cardiac Rhythm Disease Management | PMA supplement | Oct 5, 2026 | FDA | |
| BOSTON SCIENTIFIC CORPORATION | PMA supplement | Oct 2, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Biotronik, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 6024 Jean Rd., Lake Oswego, OR, 97035
Sources and methodology
- Original FDA record: P980023/S151
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records




